Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 74Terminated 25Unknown 5Active not recruiting 3Withdrawn 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Myeloid 2Plasma cell 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Congenital Abnormalities 1Burkitt Lymphoma 1

Interventions

Cytarabine 35Cyclophosphamide 30fludarabine phosphate 24fludarabine 24Rituximab 20Azacitidine 19Methotrexate 17venetoclax 16Peripheral Blood Stem Cell Transplantation 14Dasatinib 12Bendamustine Hydrochloride 12ibrutinib 11Filgrastim 11Busulfan 11Whole-Body Irradiation 10Granulocyte Colony-Stimulating Factor 10Tacrolimus 9Radiotherapy 9Lenalidomide 8Idarubicin 8Decitabine 8Vincristine 7Etoposide 7Dexamethasone 7Daunorubicin 7Cyclosporine 7merphos 6Prednisone 6Melphalan 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Alemtuzumab × Other hematologic neoplasm × Clear all
NCT00085449 2019-11-27

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00226512 2011-04-08

To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

Hadassah Medical Organization

Phase 3 Withdrawn
203 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡